Gene mutations can impair the sensitivity of cancer cells to targeted drugs, and lead to individual differences of clinical therapeutic effects. Epidermal growth factor receptor (EGFR) mutation plays an important role in therapeutic decision-making. Furthermore, some co-existing gene mutations, such as TP53 mutation, can also affect the therapeutic effect and prognosis of patients. Whether EGFR mutation combined with TP53 mutation affects the sensitivity of lung cancer cells to tyrosine kinase inhibitor (TKI) and long-term prognosis of non-small cell lung cancer (NSCLC) patients is still unknown and has attracted more attentions. However, in the current clinical practice, TP53 mutation is not a key factor of therapeutic decision-making, so further studies are needed to clarify the impact of TP53 mutation (including each subtype) on the potential benefits of EGFR-targeted therapy of NSCLC.
基因突变能够影响肺癌细胞对靶向药物的敏感性，导致个体化临床治疗效果出现差异。表皮生长因子受体(EGFR)的突变状态在内科药物治疗决策中具有重要意义。此外，其他并存的基因突变均可影响疾病的治疗效果和患者的远期临床预后。EGFR突变合并TP53突变是否可改变肺癌细胞对酪氨酸激酶抑制剂治疗的敏感性和对远期预后的影响一直受到人们的关注。目前在临床实践中，TP53的突变状态并不是临床治疗决策中的参考依据，因此需要进一步的证据阐明TP53(包括各亚型)突变状态对EGFR靶向治疗潜在获益的影响，以指导非小细胞肺癌的治疗。.
Keywords: Carcinoma, non-small-cell lung; Eepidermal growth factor receptor; Prognosis; TP53; Tyrosine kinase inhibitors.